Stephen Davis - Feb 23, 2023 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
CEO, Director
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Stock symbol
ACAD
Transactions as of
Feb 23, 2023
Transactions value $
-$72,322
Form type
4
Date filed
2/27/2023, 08:00 PM
Previous filing
Jan 10, 2023
Next filing
Apr 7, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise +10.9K +12.93% 95.6K Feb 23, 2023 Direct F1
transaction ACAD Common Stock Sale -$72.3K -3.85K -4.03% $18.78 91.7K Feb 24, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Restricted Stock Units Options Exercise $0 -10.9K -33.33% $0.00 21.9K Feb 23, 2023 Common Stock 10.9K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F3 The restricted stock units vest in four equal annual installments beginning February 23, 2022.